Florida Doc Agresti Banned from Prescribing After Fraud Conviction Hits
Published Date: 7/8/2025
Notice
Summary
Dr. Mark Agresti from Florida lost his DEA registration because he was convicted of health care fraud and excluded from federal health programs. He didn’t ask for a hearing, so the DEA canceled his registration by default. This means he can no longer legally prescribe controlled substances, effective immediately, impacting his medical practice and patients.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked; Prescribing Stopped
The DEA revoked Mark Agresti, M.D.'s Certificate of Registration No. BA2032441, effective August 6, 2025. Because his registration is revoked and future Florida registration applications are denied, he can no longer legally hold or renew a registration to prescribe controlled substances in Florida or lawfully prescribe controlled substances under that DEA number.
Mandatory Exclusion from Federal Health Programs
The record shows HHS/OIG mandatorily excluded Mark Agresti, M.D. from Medicare, Medicaid, and all Federal health care programs effective January 19, 2023, for a minimum period of 47 years. This exclusion follows his 2022 conviction for one count of conspiracy to commit health care fraud and wire fraud and 11 counts of health care fraud.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13821 — Schedules of Controlled Substances: Placement of Tianeptine in Schedule I
The DEA wants to put tianeptine, a drug with potential risks, into Schedule I, meaning it’ll be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or uses tianeptine, bringing strict rules and penalties. You’ve got until August 7, 2026, to share your thoughts before the new rules could kick in.
2026-13705 — Importer of Controlled Substances Application: Benuvia Operations, LLC.
Benuvia Operations, LLC wants to become an official importer of certain controlled substances like marijuana extract and psilocybin. People and companies involved with these drugs can share their thoughts or ask for a hearing by August 6, 2026. This move could shake up who gets to bring these substances into the U.S., so keep an eye on the deadline if you’re interested!
2026-13580 — Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put 7-hydroxymitragynine above a certain amount into Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just has this substance, bringing strict rules and penalties. The move aims to keep people safe while the government figures out the long-term plan.
2026-13581 — Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put three substances related to 7-hydroxymitragynine—Mitragynine Pseudoindoxyl, MGM-15, and MGM-16—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move aims to control these substances quickly while the DEA studies them further, affecting businesses and researchers handling these compounds.
Previous / Next Documents
Previous: 2025-12609 — Tanya Newlove, N.P.; Decision and Order
Tanya Newlove, a nurse practitioner from Illinois, lost her DEA registration because her state licenses expired and she didn’t ask for a hearing to defend herself. This means she can no longer handle controlled substances legally, effective immediately. If you’re a healthcare provider, this reminds you to keep your licenses current or risk losing important permissions.
Next: 2025-12611 — Notice of Request To Release Airport Property; Waterloo Regional Airport (ALO), Waterloo, Iowa
The FAA wants to give up two pieces of land at Waterloo Regional Airport in Iowa and is asking the public what they think. This means the airport can use the land for other things, possibly bringing in new opportunities or money. If you care about the airport or local land use, now’s the time to speak up!